| APTV |
Report |
Adjusted EPS (Q2'26) |
BEAT |
pred ~$1.46 vs. cons $1.42 |
MEDIUM |
| APTV |
Report |
Net Sales (Q2'26, New Aptiv pro forma) |
IN-LINE |
pred ~$3.32B vs. cons $3.30B |
MEDIUM |
| APTV |
Report |
Adjusted EBITDA Margin (Q2'26) |
BEAT |
pred ~17.9% vs. cons 17.6% |
MEDIUM |
| APTV |
Guide |
FY2026 Adjusted EPS |
UNCHANGED |
guide ~$5.85-6.10 ($5.95 mid) vs. cons $5.90 (FY2026) |
MEDIUM |
| APTV |
Guide |
FY2026 Net Sales |
UNCHANGED |
guide ~$12.9-13.2B ($13.05B mid) vs. cons $13.0B (FY2026) |
MEDIUM |
| APTV |
Guide |
FY2026 Bookings (>$20B target / non-auto mix) |
BETTER |
guide ~$20.5B vs. cons $20.0B (FY2026) |
LOW |
| APTV |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| APTV |
Return |
5-day cumulative residual |
+0.4% (FADE) |
A modest EPS/margin beat with reaffirmed (not raised) FY guidance gives an initial relief pop given how bearish the sequential revenue optics looked, but with 19/20 already Buy-rated and a 38% implied upside already priced for the NVIDIA/edge-AI thesis, there's limited room for further re-rating unless China inflection and bookings beat prove durable; H2 stranded-cost drag (~$100M in Q2) and continued commodity/FX headwinds mean sell-side models likely trim out-period (Q3/Q4) EBITDA margin assumptions even after a Q2 beat, pulling the multi-day drift back toward flat. |
LOW |